Asset profile
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brin…
Newest first.
amikacin liposome inhalation suspension · NCT06585020 registry update
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04677569 | Phase 3 | Completed | Nov 21, 2025 | 425 | 90 of 258 sites in the United States |
| NCT03905642 | Phase 2 | Completed | Nov 2, 2010 | 49 | 0 of 11 sites in the United States |
| NCT00775138 | Phase 2 | Completed | May 11, 2009 | 64 | 2 of 18 sites in the United States |
| NCT01315678 | Phase 3 | Completed | Jun 1, 2013 | 302 | 0 of 62 sites in the United States |
| NCT00558844 | Phase 1/2 | Completed | Jun 1, 2009 | 41 | 19 of 19 sites in the United States |
| NCT06585020 | Phase 2 | Recruiting | Dec 1, 2030 | 190 | 0 of 1 sites in the United States |
Other drugs and candidates from the same company tracked in this sector.